Navigation Links
Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference

CHAPEL HILL, N.C., March 2, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Cowen and Company 31st Annual Health Care Conference at 1:30 p.m. EST, March 7, 2011, at The Boston Marriott Copley Place in Boston.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTATM for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at Media Contacts:Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 Robert.flamm@russopartnersllc.comTony Russo, Ph.D.Russo Partners, LLC(212)

SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
2. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
3. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
4. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
7. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
8. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
9. Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
10. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
11. Savient Pharmaceuticals Announces Executive Appointments
Post Your Comments:
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... today announced that Google has adopted the Synaptics ® ... controller solutions to power its newest flagship smartphones, the ... Huawei. --> --> ... Google to provide strategic collaboration in the joint development ...
Breaking Biology News(10 mins):